Very good, jeff. Didnt he go [ cheers and applause steve from studio 6b in Rockefeller Center in the heart of new york city, its the tonight show starring jimmy fallon. Tonight, join jimmy and his guests cameron diaz guy raz. Musical guest, Eslabon Armado featuring Gabito Ballesteros and the legendary roots crew questlove 1861 steve and now, here he is, jimmy fallon [ cheers and applause [ cheers and applause jimmy thank you come on. Whoa hot crowd. Thank you very, very much. Enjoy yourself, enjoy yourself welcome, welcome, welcome to the tonight show. Youre here. Thank you. You made it. [ cheers and applause thank you for watching at home fun show tonight cameron diaz on the show tonight. Thats our pal [ cheers and applause lets get to news, guys. Well, it finally happened. After more than three weeks without a speaker, republicans got on the same page and elected mike johnson as the new speaker of the house yep. They found someone just in time, if the job stayed open any longer, it w
That they are clearly understood by the companies in terms of what time lines will be. And i i think no doubt it is an area where we can often be more efficient and responsive than we have been and we are committed to trying to do the best job possible but not knowing the specifics, i cant tell you i do believe i saw a letter from you that we are moving forward on sad in a relatively timely way, but i will get back to you on your specific query, and more broadly i would say over the last couple years we have been working hard to streamline and modernize our regulatory systems to address the business process issues that slows things down and recognize the importance of good communication with companies around these kinds of activities. I understand breakthroughs in medical science and pharmaceuticals and devices sometimes, the goals are used and you have to determine which one they are. That is true. In this arena as in many other arenas, sometimes our authorities were first established
Addressing the backlog in critical ways. Import may also addressing the issues of expanding our inspectioinspectio nal capacity so that we can do those critical inspections. Which increasingly are often overseas but we are not where we need to be yet. We are committed to moving forward and we have made progress but there is a lot more work to be done. I will submit some Additional Information that i would like, how many applications the agency has received for the first generic products and how many miss the approval of the earliest possible date in what you are doing to ensure that the future generic applications are reviewed. So maybe some more detail of that. Again i thank you for being here today to answer our questions. We dont get this opportunity very often and you have done an outstanding job. Thank you. Thank you senator enzi. When we did the reauthorization of the fda user fees, we worked closely with you and your Ranking Member of this committee was chairman harkin to make s
From her Previous Post that new yorks department of Public Health and Mental Hygiene and the u. S. Department of health and human services. And dr. Hamburg, we thank you for sharing your expertise with the committee and being here today. Your statement which is an extensive statement, which i got through yesterday, last night, it will be a part of the record in its entirety. Id like to ask maybe, giddy up to 10 minutes to go through that, if youd like rather than just five, but maybe, however close you can keep it but below 10 minutes. Im going to request the record remain open for 10 days for senator smiths statement or questions for the record. A couple things, at 10 30 i have to leave. You probably do, too. Both of us have to leave. [inaudible conversations] good. And then i think, well, we have i think senator franken said he will take over at that time if we continue on beyond that, beyond that time but we are managing a bill on the floor that we have to leave four at 10 30. So ag
And also one of the things that excites me is developing computer simulations and models so that you can actually study some of these devices in that context instead of in animal models or people in the early stages so that you can really number one manipulate things and play with it more but also reduce costs and potential risks to patients but still really get import information to again moved things that have promise into the marketplace and making a difference in peoples lives. So i think its a wonderful public credit partnership. Thank you for your leadership in helping to make it possible and we are very committed to working with it read we are seeing the benefits already and we see more importantly a foundation for lots more progress. Well thank you for your role in that and for your excitement about it. Senator enzi. Thank you mr. Chairman. I would like to revisit the goals you immediately identified when he took the helm at the fda modernizing how the agency considers new ther